These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23168176)

  • 41. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
    Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro.
    Bilir A; Altinoz MA; Attar E; Erkan M; Aydiner A
    Neoplasma; 2002; 49(1):38-42. PubMed ID: 12044058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
    Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):34-8. PubMed ID: 7939761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
    Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer.
    Neijt JP; du Bois A
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):78-83. PubMed ID: 10190786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
    Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells.
    Barnes AP; Miller BE; Kucera GL
    Gynecol Oncol; 2007 Feb; 104(2):443-50. PubMed ID: 16996114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
    Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients.
    Agiostratidou G; Sgouros I; Galani E; Voulgari A; Chondrogianni N; Samantas E; Dimopoulos MA; Skarlos D; Gonos ES
    Anticancer Res; 2001; 21(1A):455-9. PubMed ID: 11299779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
    Waltmire CN; Alberts DS; Dorr RT
    Anticancer Drugs; 2001 Aug; 12(7):595-602. PubMed ID: 11487716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of alvocidib and carboplatin on ovarian cancer cells in vitro.
    Baumann KH; Kim H; Rinke J; Plaum T; Wagner U; Reinartz S
    Exp Oncol; 2013 Sep; 35(3):168-73. PubMed ID: 24084453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
    Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
    Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
    Engle DB; Belisle JA; Gubbels JA; Petrie SE; Hutson PR; Kushner DM; Patankar MS
    Gynecol Oncol; 2009 Mar; 112(3):631-6. PubMed ID: 19263582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
    Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
    Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers.
    He H; Yu T; Zhang Y
    Ultraschall Med; 2012 Jun; 33(3):275-82. PubMed ID: 21165815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
    Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
    Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.
    Wang Z; Lee KB; Reed E; Sinha BK
    Int J Cancer; 1996 Nov; 68(5):583-7. PubMed ID: 8938138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.